Skip to content

Contact +44 (0) 20 7060 7474 email us

Medical Devices

United States Woundcare Management Medical Equipment Industry Report

Detailed Analysis of the Medical Equipment & Medical Devices Market Covering Advanced and Traditional Wound Management, Compression Therapy, Ostomy and Wound Closure Devices Medical Equipment and Supplies

Publication Date April 2008
Publisher Global Markets Direct
Product Type Report
Pages 307
ISBN Number not applicable
Product Code GMD00479

Price

£1,980.00
approximately: $2,998 | €2,210

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

United States Woundcare Management Medical Equipment Industry Report

Summary

This report is an essential source for in-depth information and data relating to United States woundcare management medical equipment market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the woundcare management medical equipment in United States.

Scope

  • The report provides sector information broken down into detailed categories and segments in country.
  • Total revenues, products sold, end users, and average pricing.
  • Market shares of all the key competitors.
  • Key pipeline products that are set to shape the market, broken down by sector.
  • Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
  • Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
  • Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
  • Key mergers and acquisitions, partnerships, private equity investments and IPOs.
  • Customer, hospitals and physicians data.

Reasons to buy

  • Gain a strong understanding of the industry at a global level, with break downs for the country
  • Evaluate and compare the attractiveness of the market in the country.
  • Identify growth segments and opportunities in each industry sector within the country.
  • Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
  • Analyze the competitiveness of the market in the country and identify hotspots.
  • Develop strategies based on the latest product, brand, expansion and research and development news in the country.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
  • Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Contents

  • 1 Table Of Contents
    • 1.1 1.2 2 Introduction
    • 2.1 What Is This Report About?
    • 2.2 Definitions
      • 2.2.1 Wound Care Management
        • 2.2.1.1 Traditional Wound Management
        • 2.2.1.2 Advanced Wound Management
        • 2.2.1.3 Wound Closure Devices
        • 2.2.1.4 Ostomy
        • 2.2.1.5 Compression Therapy
  • 3 Healthcare Sector Review
    • 3.1 Healthcare Expenditure
    • 3.2 Healthcare Infrastructure
      • 3.2.1 Healthcare Personnel Data
      • 3.2.2 Healthcare Facilities Data
  • 4 Wound Care Mangement in United States
    • 4.1 Wound Care Management Overall Revenues (2000-2012)
    • 4.2 Wound Care Management Overall Volume (2000-2012)
    • 4.3 Wound Care Management Overall Company Shares (2005-2006)
  • 5 Wound Closure Devices in United States
    • 5.1 Wound Closure Devices Overall Revenues (2000-2012)
      • 5.1.1 Skin Closure Devices Overall Revenues (2000-2012)
      • 5.1.2 Hemostats Overall Revenues (2000-2012)
      • 5.1.3 Tissue Sealants Overall Revenues (2000-2012)
    • 5.2 Wound Closure Devices Overall Volume (2000-2012)
      • 5.2.1 Skin Closure Devices Overall Volume (2000-2012)
      • 5.2.2 Hemostats Overall Volume (2000-2012)
      • 5.2.3 Tissue Sealants Overall Volume (2000-2012)
    • 5.3 Wound Closure Devices Average Price (2000-2012)
      • 5.3.1 Hemostats Average Price (2000-2012)
      • 5.3.2 Tissue Sealants Average Price (2000-2012)
      • 5.3.3 Skin Closure Devices Average Price (2000-2012)
    • 5.4 Wound Closure Devices Distribution Share
    • 5.5 Wound Closure Devices Company Share
  • 6 Ostomy in United States
    • 6.1 Ostomy Overall revenues (2000-2012)
    • 6.2 Ostomy Category Overall Volume (2000-2012)
    • 6.3 Ostomy Average Price (2000-2012)
    • 6.4 Ostomy Distribution Share (2005-2006)
    • 6.5 Ostomy Company Share (2005-2006)
  • 7 Advanced Wound Management in United States
    • 7.1 Advanced Wound Management Revenue (2000-2012)
    • 7.2 Advanced Wound Management Overall Volume (2000-2012)
    • 7.3 Advanced Wound Management Average Price (2000-2012)
    • 7.4 Advanced Wound Management Distribution Share (2005-2006)
    • 7.5 Advanced Wound Management Company Share (2005-2006)
  • 8 Traditional Wound Management in United States
    • 8.1 Traditional Wound Management Overall Revenue (2000-2012)
    • 8.2 Traditional Wound Management Overall Volume (2000-2012)
    • 8.3 Traditional Wound Management Average Price (2000-2012)
    • 8.4 Traditional Wound Management Distribution Share (2005-2006)
    • 8.5 Traditional Wound Management Company Share (2005-2006)
  • 9 Compression Therapy in United States
    • 9.1 Compression Therapy Category Revenue (2000-2012)
    • 9.2 Compression Therapy Category Volume (2000-2012)
    • 9.3 Compression Therapy Average Price (2000-2012)
    • 9.4 Compression Therapy Distribution Share (2005-2006)
    • 9.5 Compression Therapy Company Share (2005-2006)
  • 10 Baxter International Company Profile
    • 10.1 Company Overview
    • 10.2 Business Overview
      • 10.2.1 BioScience
      • 10.2.2 Medication Delivery
      • 10.2.3 Renal
      • 10.2.4 Products
      • 10.2.5 History
    • 10.3 Value Chain Analysis
      • 10.3.1 Manufacturing
      • 10.3.2 Product Development
      • 10.3.3 Sales and Marketing
    • 10.4 SWOT Analysis
      • 10.4.1 Baxter International Inc. Strengths
      • 10.4.2 Baxter International Inc. Weaknesses
      • 10.4.3 Baxter International Inc. Opportunities
      • 10.4.4 Baxter International Inc. Threats
    • 10.5 Financial and Operational Review
    • 10.6 Locations And Subsidiaries
    • 10.7 Financial Deals Landscape
      • 10.7.1 Baiyunshan And Baxter Form A Joint Venture In China
      • 10.7.2 Baxter Signs Licensing Agreement With Intercytex And Spinal Restoration
      • 10.7.3 Baxter Sells Transfusion Therapies Business to Texas Pacific and Maverick Capital
      • 10.7.4 B. Braun Acquires Renal Therapy Business Of Baxter
      • 10.7.5 Innovata signs a license agreement with Baxter International
      • 10.7.6 Kuros Biosurgery Signs An Agreement With Baxter International
      • 10.7.7 Gambro Signs An Agreement With Baxter
      • 10.7.8 Baxter Healthcare And Gambro Enter Into An Agreement
      • 10.7.9 Baxter and Cerus Enter Into Agreement With BioOne for Commercialization Of INTERCEPT Blood System
      • 10.7.10 Baxter International And Kaketsuken Enter Into Agreement
      • 10.7.11 Baxter To Acquire 40% Stake In Shanghai Baxter From Worldbest Treeful
    • 10.8 Recent Developments
      • 10.8.1 Jan 24, 2008: Baxter Achieves Record Sales and Earnings for Full-Year 2007
      • 10.8.2 Dec 18, 2007: Baxter Elects CFO
      • 10.8.3 Nov 13, 2007: Baxter Declares Quarterly Dividend
      • 10.8.4 Aug 01, 2007: Baxter Elects New Board Director
      • 10.8.5 Jul 31, 2007: Baxter Announces Quarterly Dividend
      • 10.8.6 Mar 13, 2007: Baxter Declares Additional Share Repurchase Authorization
      • 10.8.7 Feb 13, 2007: Baxter Announces Quarterly Dividend
      • 10.8.8 Nov 28, 2006: Baxter Announces Annual Dividend
      • 10.8.9 Sep 14, 2006: Baxter Appoints President, Baxter Latin America
    • 10.9 Baxter International Inc. Pipeline Products
      • 10.9.1 Next-Generation Home Hemodialysis Machine
        • 10.9.1.1 Product Overview
        • 10.9.1.2 Product Description
        • 10.9.1.3 Product Status
        • 10.9.1.4 Product Milestone
  • 11 Covidien Ltd./Tyco Healthcare Company Profile
    • 11.1 Company Overview
    • 11.2 Business Overview
      • 11.2.1 Imaging Solutions
      • 11.2.2 Medical Devices
      • 11.2.3 Medical Supplies
      • 11.2.4 Pharmaceutical Products
      • 11.2.5 Retail Products
      • 11.2.6 Products
      • 11.2.7 History
    • 11.3 Value Chain Analysis
      • 11.3.1 Manufacturing
      • 11.3.2 Product Development
      • 11.3.3 Sales and Marketing
    • 11.4 SWOT Analysis
      • 11.4.1 Covidien Ltd./Tyco Healthcare Strengths
      • 11.4.2 Covidien Ltd./Tyco Healthcare Weaknesses
      • 11.4.3 Covidien Ltd./Tyco Healthcare Opportunities
      • 11.4.4 Covidien Ltd./Tyco Healthcare Threats
    • 11.5 Financial and Operational Review
      • 11.5.1 Financial Statements
      • 11.5.2 Financial Ratios
    • 11.6 Locations And Subsidiaries
    • 11.7 Financial Deals Landscape
      • 11.7.1 Covidien Signs An Agreement With Allergan
      • 11.7.2 Covidien Acquires Scandius Biomedical
      • 11.7.3 Covidien International Finance Completes Private Placement Of $2,750 Million
      • 11.7.4 Covidien And BioSynthema Enter Into Licensing Agreement
      • 11.7.5 Integra LifeSciences Acquires Assets Of Radionics Division From Covidien
      • 11.7.6 Covidien To Sell European Incontinence Business
      • 11.7.7 Covidien To Acquire Tissue Science Laboratories
    • 11.8 Recent Developments
      • 11.8.1 Mar 28, 2008: Covidien Spends $760,000 Lobbying Federal Government In 2007
      • 11.8.2 Mar 18, 2008: Covidien Declares Quarterly Dividend
      • 11.8.3 Feb 21, 2008: Covidien Gests Favorable Decision In Patent Litigation Case
      • 11.8.4 Feb 07, 2008: Covidien Declares Q1 Fiscal 2008 Results
      • 11.8.5 Jan 15, 2008: Covidien Declares Quarterly Dividend
      • 11.8.6 Jan 10, 2008: Covidien To Declare Q1 Fiscal 2008 Results
      • 11.8.7 Dec 06, 2007: Covidien Reports Q4 Fiscal 2007 Results
      • 11.8.8 Oct 04, 2007: Covidien And NewSouth Innovations Collaborate To Develop Novel Imaging Agent
      • 11.8.9 Sep 28, 2007: Covidien Declares Quarterly Dividend
      • 11.8.10 Aug 09, 2007: Covidien Declares Q3 Fiscal 2007 Results
    • 11.9 Covidien Ltd./Tyco Healthcare Pipeline Products
      • 11.9.1 PleuraSeal Lung Sealant System
        • 11.9.1.1 Product Overview
        • 11.9.1.2 Product Description
        • 11.9.1.3 Product Status
        • 11.9.1.4 Product Milestone
      • 11.9.2 Sandman Intro CPAP Device
        • 11.9.2.1 Product Overview
        • 11.9.2.2 Product Description
        • 11.9.2.3 Product Status
        • 11.9.2.4 Product Milestone
  • 12 3M Company Profile
    • 12.1 Company Overview
    • 12.2 Business Overview
      • 12.2.1 Consumer and Office
      • 12.2.2 Display and Graphics
      • 12.2.3 Electro and Communications
      • 12.2.4 Health Care
      • 12.2.5 Industrial and Transportation
      • 12.2.6 Safety, Security and Protection Services
      • 12.2.7 Products
    • 12.3 Value Chain Analysis
      • 12.3.1 Manufacturing
      • 12.3.2 Product Development
      • 12.3.3 Sales and Marketing
    • 12.4 SWOT Analysis
      • 12.4.1 3M Company Strengths
      • 12.4.2 3M Company Weaknesses
      • 12.4.3 3M Company Opportunities
      • 12.4.4 3M Company Threats
    • 12.5 Financial and Operational Review
    • 12.6 Locations And Subsidiaries
      • 12.6.1 Other Locations & Subsidiaries
    • 12.7 Financial Deals Landscape
      • 12.7.1 3M Canada Acquires Les Entreprises Solumed
      • 12.7.2 3M Acquires Bondo
      • 12.7.3 3M Acquires Lingualcare
      • 12.7.4 3M Acquires Abzil Industria E Comercio
      • 12.7.5 3M Acquires Neo Plast
      • 12.7.6 3M Acquires Assets Of DMS Chile
      • 12.7.7 3M Acquires Business Of Innovative Paper Technologies
      • 12.7.8 3M Acquires Powell
      • 12.7.9 Gen-Probe Signs An Agreement With 3M Company
      • 12.7.10 3M Acquires Acolyte Biomedica
      • 12.7.11 3M Acquires Sealed Air Corp.'S Interest In Polymask Corp
      • 12.7.12 3M Sells Its Pharmaceutical Business To Meda AB
      • 12.7.13 3M Acquires SoftMed Systems
      • 12.7.14 3M Sells its Pharmaceuticals Business to Graceway
      • 12.7.15 Gen-Probe Signs An Agreement With 3M
      • 12.7.16 3M Sells its Pharmaceutical Operations in the Asia Pacific Region to Ironbridge Capital and Archer Capital
      • 12.7.17 3M Acquires Biotrace International
      • 12.7.18 Ekahau Secures $16 Million In Additional Funding
      • 12.7.19 3M Acquires Brontes Technologies
      • 12.7.20 3M acquires Nylonge Corp
      • 12.7.21 3M Signs An Agreement With ClozeX Medical
      • 12.7.22 3M Acquires OMNII Oral Pharmaceuticals
      • 12.7.23 3M Sells Pharmaceutical Operations In The United States To Graceway
      • 12.7.24 3M Sells Pharmaceutical Business In Europe To Meda AB
      • 12.7.25 3M Sells Pharmaceutical Operations In The Asia Pacific To Ironbridge and Archer Capital
      • 12.7.26 3M Acquires Accuspray Application Technologies Inc
      • 12.7.27 3M to acquire Rochford Thompson Equipment
      • 12.7.28 3M To Acquire Aearo Technologies From Permira
      • 12.7.29 Permira To Sell Aearo Technologies To 3M
    • 12.8 Recent Developments
      • 12.8.1 Mar 31, 2008: HighJump Software Introduces Survey Management Solution for Direct Store Delivery Businesses
      • 12.8.2 Mar 24, 2008: Brazil's Companhia de Transmissao de Energia Eletrica Paulista Chooses 3M ACCR for Upgrade of Line Over Parana River in Sao Paulo State
      • 12.8.3 Mar 19, 2008: 3M to Headquarter Optical Systems Business in Asia
      • 12.8.4 Mar 19, 2008: 3M To Headquarter Optical Systems Business In North Asia
      • 12.8.5 Feb 11, 2008: 3M Increases Dividend for the 50th Straight Year
      • 12.8.6 Nov 12, 2007: 3M Declares Quarterly Dividend
      • 12.8.7 Oct 24, 2007: 3M And Sanyo Settle Suit On Lithium Ion Battery
      • 12.8.8 Aug 13, 2007: 3M Declares Quarterly Dividend
      • 12.8.9 May 08, 2007: 3M Declares Quarterly Dividend
      • 12.8.10 Apr 30, 2007: Gen-Probe And 3M Collaborate To Develop Rapid Molecular Tests
  • 13 Ethicon, Inc. Company Profile
    • 13.1 Company Overview
    • 13.2 Business Overview
      • 13.2.1 Products
    • 13.3 Locations And Subsidiaries
    • 13.4 Financial Deals Landscape
      • 13.4.1 Edwards Lifesciences Acquires CardioVations Product Line From ETHICON
      • 13.4.2 Musculoskeletal Transplant Signs Marketing Agreement With ETHICON
      • 13.4.3 ETHICON Acquires Vascular Control Systems
      • 13.4.4 Datascope Acquires Endoscopic Vessel Harvesting Business From ETHICON
  • 14 Smith & Nephew Plc Company Profile
    • 14.1 Company Overview
    • 14.2 Business Overview
      • 14.2.1 Advanced Wound Management
      • 14.2.2 Endoscopy
      • 14.2.3 Reconstruction
      • 14.2.4 Trauma and Clinical Therapies
      • 14.2.5 Products
      • 14.2.6 History
    • 14.3 Value Chain Analysis
      • 14.3.1 Manufacturing
      • 14.3.2 Product Development
      • 14.3.3 Sales and Marketing
    • 14.4 SWOT Analysis
      • 14.4.1 Smith & Nephew Plc Strengths
      • 14.4.2 Smith & Nephew Plc Weaknesses
      • 14.4.3 Smith & Nephew Plc Opportunities
      • 14.4.4 Smith & Nephew Plc Threats
    • 14.5 Financial and Operational Review
    • 14.6 Locations And Subsidiaries
    • 14.7 Financial Deals Landscape
      • 14.7.1 Smith & Nephew Endoscopy Sells Its Vascular Business To InaVein
      • 14.7.2 Smith & Nephew Signs An Agreement With Universal Hospital Services
      • 14.7.3 Smith & Nephew Acquires Plus Orthopedics Holding
      • 14.7.4 Smith & Nephew And Teknimed Enter Into Distribution Agreement
      • 14.7.5 Smith & Nephew Acquires BlueSky Medical Group
      • 14.7.6 Smith & Nephew Enters Into An Agreement With Covalon
      • 14.7.7 Smith & Nephew Signs An Agreement With UDL Laboratories
      • 14.7.8 Nexa Orthopedics Signs An Agreement With Smith & Nephew
      • 14.7.9 Smith & Nephew Acquires Osteobiologics
      • 14.7.10 Smith & Nephew And Q-MED Enter Into Licensing Agreement
      • 14.7.11 Smith & Nephew Completes Sale Of 50% Interest In BSN Medical To Montagu Private Equity
      • 14.7.12 ArthroCare Enters Into Licensing Agreement With Smith & Nephew
      • 14.7.13 Smith & Nephew Signs Licensing Agreement With Alexandria Research Technologies
      • 14.7.14 Smith & Nephew Signs An Agreement With ORTHOsoft
      • 14.7.15 Osteotech And Smith & Nephew Enter Into Processing And Distribution Agreement
      • 14.7.16 Smith & Nephew Acquires VERSAJET From HydroCision
      • 14.7.17 Smith & Nephew Terminates Acquisition Of Biomet
    • 14.8 Recent Developments
      • 14.8.1 Apr 02, 2008: Smith & Nephew Declares Second Interim Dividend
      • 14.8.2 Apr 02, 2008: Smith & Nephew Reports 2007 Results
      • 14.8.3 Mar 23, 2008: Smith & Nephew, Corin Battle To Win Over America's Hip Generation
      • 14.8.4 Feb 29, 2008: Smith & Nephew Appoints SVP, GM
      • 14.8.5 Feb 20, 2008: Smith & Nephew and Synthes Settle Patent Dispute For Trochanteric Fixation Nails
      • 14.8.6 Oct 22, 2007: Smith & Nephew Declares Interim Dividend
      • 14.8.7 May 03, 2007: Smith & Nephew Appoints New CEO
    • 14.9 Smith & Nephew Plc Pipeline Products
      • 14.9.1 R3 Modular resurfacing Acetabular system
        • 14.9.1.1 Product Overview
        • 14.9.1.2 Product Description
        • 14.9.1.3 Product Status
      • 14.9.2 R3 Ceramic-on-ceramic Acetabular System
        • 14.9.2.1 Product Overview
        • 14.9.2.2 Product Description
        • 14.9.2.3 Product Status
  • 15 Regulation System
    • 15.1 Medical Equipment Approval Process
      • 15.1.1 Pre-market Approval Process
      • 15.1.2 Intended use and Indications for use
      • 15.1.3 Predicate Device
      • 15.1.4 Safe and Effective
      • 15.1.5 Other Category Devices
      • 15.1.6 Post-Market Approval Process
      • 15.1.7 Compliance and Enforcement
      • 15.1.8 Registration Fee
      • 15.1.9 Approval Time
  • 16 Pricing and Reimbursement
    • 16.1 Government Policies
    • 16.2 Private Insurance
    • 16.3 Diagnosis Related Groups (DRG)
  • 17 Distribution Structure
    • 17.1 Distribution Structure
  • 18 APPENDIX
    • 18.1 Methodology
    • 18.2 Currency Conversion
    • 18.3 Contact Us
    • 18.4 Disclaimer